Symbol not found

:CYDY   00:00AM GMT
0.00
0.00 (0.00%)
Products

Cytodyn Submits Breakthrough Therapy Designation Application To FDA For Leronlimab As A Treatment For Metastatic Triple-Negative Breast Cancer

Published: 11/08/2021 11:15 GMT
(CYDY) - Cytodyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab As a Treatment for Metastatic Triple-negative Breast Cancer (mtnbc); Fast Track Designation for Mtnbc Was Received Previously.